On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...

The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

Bavarian Nordic, with a diverse vaccine portfolio and $340 million in contracts for 2025, offers growth potential for ...

Vir Biotechnology (VIR) “announced that the European Medicines Agency Committee for Orphan Medicinal Products, has issued a positive opinion on ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Healthcare products provider RHEA Generics is committed to promoting affordable healthcare by offering generic medications ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

The European Union health agency on Monday warned that Europe was set to miss goals on reducing the use of antibiotics, ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

(RTTNews) - Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended ...

A new study reveals that more than half of cancer drugs approved by the FDA under accelerated pathways are not authorized in ...